Stéphane RAGUSA

About Stéphane RAGUSA

Stéphane Ragusa is the founder and Chief Executive Officer of Predilife, a French pioneer in predictive medicine that was listed on Euronext Growth in 2018. He founded the company in 2004 with a clear ambition: to make personalized prevention more accessible by combining medical data, artificial intelligence, and statistical modeling in healthcare. His career sits at the crossroads of mathematics, biology, and medicine. He is an alumnus of École Polytechnique, holds a doctorate in biology, and has served as an associate professor in medical statistics. He also worked at the Gustave Roussy cancer center, where he observed firsthand the challenge of anticipating disease risk and where the idea behind Predilife took shape. As Predilife’s leader, Ragusa oversaw a long period of research and development that led to medical device certification and the commercialization of predictive screening solutions. These include individualized assessments for breast cancer risk as well as broader multi-condition preventive check-ups. Under his leadership, the company built a distinctive position in a highly specialized field: turning clinical and statistical data into decision-support tools for patients, physicians, and, more recently, employers. He guided Predilife through its market debut while reinforcing its scientific identity and medical credibility. Ragusa’s expertise spans predictive modeling, medical statistics, artificial intelligence in healthcare, and the development of regulated medical products. As a listed-company executive, he combines scientific legitimacy with entrepreneurial discipline and strategic execution. He is also a significant reference shareholder, reflecting a long-term commitment to the company’s industrial and medical vision. Beyond day-to-day management, Stéphane Ragusa has consistently defended a strong conviction: predictive medicine can improve prevention, accelerate earlier diagnosis, and support more personalized care pathways. That conviction continues to define Predilife’s corporate strategy and public positioning, and it remains the core of his reputation as a French executive in innovative healthcare.